Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Why Aquinox Pharmaceuticals (AQXP) Should be on Every Investor’s Radar

Canadian biotech Aquinox Pharmaceuticals (NASDAQ: AQXP) created quite the industry buzz last week when the company reported positive mid-stage trial results for its bladder pain drug, AQX-1125.

In addition to meeting secondary endpoints, the LEADERSHIP trial also demonstrated that a high proportion of patients (49%) achieved a clinically meaningful improvement in pain (2 points or greater on an 11-point NRS scale) as compared to placebo (39%).

“Consistently positive results from multiple secondary endpoints have strengthened our confidence in further development of AQX-1125 for BPS/IC,” David Main, president and CEO of Aquinox stated in the news release. “The encouraging effect of AQX-1125 observed on the primary endpoint of reduction in pain together with several statistically significant secondary endpoints, underscore the potential of AQX-1125 as a once daily, oral therapy for this debilitating disease.”

Aquinox also provided a general business update, recapping news from July when the company reported negative FLAGSHIP trial results for AQX-1125 as treatment for chronic pulmonary disease (COPD). As such, the company said it is not planning further development of AQX-1125 as a potential treatment for COPD.

Aquinox instead is reallocating resources to the prioritization of its activities to support possible future registration and planned pivotal clinical trials with AQX-1125 for bladder pain syndrome/interstitial cystitis (BPS/IC) and is deferring the initiation of its phase 2 trial in chronic rhinosinusitis with nasal polyps.

Also on deck is approaching top line data in KINSHIP, a phase 2 clinical trial to evaluate the safety and efficacy of AQX-1125 in atopic dermatitis. Target enrollment in the KINSHIP trial was achieved in early May 2015, and the company anticipates top line data from the trial in Q4 2015.

With Aquinox successfully advancing AQX-1125 for the treatment of a disease affecting between 5 and 12 million Americans each year, the company is aptly positioned to drive shareholder value – warranting a second glance at the small company making big waves in the biotech market.

For more information visit

This entry was posted in Small Cap News. Bookmark the permalink.

Comments are closed.